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Abstract
A serological survey was performed to determine the preva-
lence of antibodies against human bocavirus in an Apulian popu-
lation. Anti-hBoV IgG antibodies were analysed in 1206
inhabitants (age range, 1 month–84 years) using a standardized
ELISA test based on the use of recombinant hBoV VP2 virus-like
particles. In total, 1075 (89.1%) of 1206 participants (mean age
32 ± 24.8 years) displayed anti-hBoV-IgG. The seroprevalence
increased significantly (p < 0.0001) in children from 2–4 years
(64.2%) to 5–9 years (96.4%). A similar trend was observed in
both male and female subjects. In conclusion, our results show
that hBoV infection is common in this population, especially in
children.
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Human bocavirus (hBoV) is a newly identified human parvo-
virus associated with respiratory tract infections [1]. Until
now four genetic subgroups of hBoV were known to infect
humans (hBoV1–4) [1–4]. HBoV1 has been shown to be pre-
valent in upper and lower respiratory tract infections, fre-
quently in association with other viruses, but has been also
detected in serum, urine and faecal samples [5–11]. HBoV1
isolates show a low degree of genetic variability [4]. HBoV2–
4 isolates share between 67 and 80% of nucleotide
sequences with hBoV1 [2,3]. They have been mainly detected
in patients with infection of the gastrointestinal tract, and
rarely in those with infection of the respiratory tract [12].
Most of the epidemiological and clinical studies have been
conducted on children and hospitalized paediatric patients
with respiratory infections. Therefore the results may not
reflect the real seroprevalence of hBoV in the general popula-
tion [13]. Moreover, the high presence of co-infections with
other respiratory viruses may complicate the analysis of clini-
cal, virological and serological aspects in hBoV infection [8,14].
Only a few studies have been conducted to evaluate the
seroprevalence of hBoV in the general population that are
not representative of the virus spread in all age groups [5–
16]. We performed a regional cross-sectional population-
based study to estimate the prevalence of hBoV-specific IgG
in Apulia, south Italy. Serum specimens were collected from
healthy subjects, who were not hospitalized, and frozen at
)80C until use. In particular, the serum samples were resid-
ual sera from subjects who applied for a health check. Age,
gender and date of sampling were reported for each case.
Local ethics committees approved this study and informed
consent was obtained. Immunocompromised patients, recipi-
ents of blood transfusion during the previous 6 months and
individuals suffering from acute infectious disease were
excluded from the study.
A total of 1206 samples were collected from June 2009 to
May 2010 (0–5 months, n = 38; 6–11 months, n = 35; 1 year,
n = 67; 2–4 years, n = 81; 5–9 years, n = 139; 10–14 years,
n = 89; 15–19 years, n = 112; 20–29 years, n = 105; 30–
39 years, n = 106; 40–49 years, n = 104; 50–59 years,
n = 105; 60–69 years, n = 112; ‡70 years, n = 113). All sam-
ples had to be equally representative of male and female sub-
jects. IgG-antibodies against hBoV VP2-proteins were
quantified using a standardized ELISA based on VP2 virus-like
particles (VLP) as antigen [15].
Assuming an overall hBoV prevalence of 85%, 1200 sam-
ples were required to achieve 95% confidence level, with a
precision of the estimate of 7% and with a study power of
80.0%. The statistical analysis was performed using STAT-
VIEW5.1 (STATVIEW, Berkeley, CA, USA). Differences
between percentages have been assessed using the chi-
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squared test and Fisher’s exact test as needed. Comparison
between geometric mean titres (GMT) was assessed by two-
tailed unpaired Student’s t-test. A p value <0.05 was consid-
ered statistically significant.
One thousand and seventy-five out of 1206 analysed sam-
ples (89.1%; age range, 1 month to 84 years) were tested
positive for hBoV-specific IgG, 126 (10.4%) negative and 5
(0.4%) equivocal. Anti-hBoV-IgG was detected in 73.7% of
infants aged 0–5 months and in 51.4% (p < 0.05) of the age
group 6–11 months. The seropositive rate increased signifi-
cantly between the age groups of 2–4 years (64.2%) and 5–
9 years (96.4%; p < 0.0001). Similar trends were observed by
testing the respective age groups of male subjects (65.8% vs.
95.6%; p < 0.0001) and female subjects (62.8% vs. 97.2%;
p < 0.0001) (Fig. 1). In children aged >2–4 years seropreva-
lence increased to more than 90%. Geometric Mean Titre
(GMT) value ranged from 1052.6 ± 61.7 Relative Units (RU)
(0–5 months) to 912.2 ± 271.5 RU (age ‡70 years), with a
peak of 1398.5 ± 278.3 RU in those aged 1 year. A signifi-
cant decrease (p < 0.05) was observed for GMT in girls at
the age of 1 year vs. 2–4 years (1684.6 ± 168.2 RU/mL vs.
1010.2 ± 203.4 RU/mL) and among those aged 20–29 vs. 30–
39 years (1245.1 ± 442.7 RU/mL vs. 741.2 ± 218.1 RU/mL)
(Fig. 2).
This is the first report that evaluates the seroepidemiol-
ogy of hBoV1 infection in Italy. In this study we examined
the prevalence of hBoV-specific IgG antibodies in serum
samples from individuals up to an age of more than
70 years. Our data indicate hBoV infection to be ubiquitous
in the general population and to be acquired early in pre-
school children. More than 90% of subjects older than
4 years displayed previous exposure to hBoV. The high se-
roprevalence that was observed in newborns and in chil-
dren during the first months of life is assumed to be
related to maternal antibodies; decreasing values were
observed in the group of children aged 6–11 months. The
results showed that primary hBoV infection occurs between
6 and 48 months, as previously described [14]. Our data
show a similar trend to that observed in the few serologi-
cal studies [8,13,16,17]. However, the overall seropreva-
lence (89.1%) is higher than that observed by Zhao et al.
(59.1%) [16] and Endo et al. (71.1%) [17]. This could be
due to testing a sample size that may be more representa-
tive of the general population or to geographical variations
in hBoV epidemiology.
A recent study showed both intergenotypical and intra-
genotypical recombinants to occur between hBoV1 and
hBoV4 and between hBoV2 variants, respectively [12].
About 80% of genomic organization of VP1 and VP2 anti-
gens is identical [3] but the VP2 antigen seems to be the
most conserved and immunogenic protein [18]. The high
hBoV1 IgG prevalence could be due to cross-reactivities
among VP2 antigens of hBoV1 and hBoV2-4 [12], thereby
resulting in an overestimation of hBoV1 circulation. This
interpretation could explain the high isolation rate of hBoV1
found in adult patients with influenza-like illness (ILI) [19]. It
remains to be clarified whether antibodies produced against
a specific hBoV genotype may also neutralize related variants
of hBoV. Such cross-immunity might have clinical relevance
in the management of respiratory and gastrointestinal hBoV-
correlated infections.
The presence and the high hBoV load in respiratory tract
infections, frequently associated with other viruses, implies
an important role in the pathogenesis of respiratory diseases
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FIG. 1. Human bocavirus seroprevalence by age group and gender
in Apulia, 2009–2010. Statistical analysis was performed by Fisher’s
exact test and/or the v2 test: *p < 0.05 between total groups of 0–5
months and 6–11 months; **p < 0.0001 between total groups of 2–4
years and 5–9 years, male subjects of 2–4 years and 5–9 years, and
female subjects of 2–4 years and 5–9 years.
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FIG. 2. Geometric mean titre (RU/mL) stratified by gender and age
group in Apulia, 2009–2010. Values are given as mean ± standard
deviation. Statistical analysis was performed by unpaired t-test:
*p < 0.05 between female subjects of 1 year and 2–4 years, and
between female groups of 20–29 years and 30–39 years.
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[20], but the real pathogenic significance of the virus needs
to be further elucidated.
In conclusion, our results show the frequent circulation of
hBoV in the general population. Further studies are needed
to determine the exact clinical and epidemiological role of
hBoV.
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